Drug intelligence / Profile preview

bevacizumab + camrelizumab + everolimus + famitinib + nab-paclitaxel + pyrotinib

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy regimen consisting of six different anticancer agents with complementary mechanisms of action: - Bevacizumab: A humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis - Camrelizumab: A PD-1 inhibitor that enhances T-cell immune responses against cancer cells - Everolimus: An mTOR inhibitor that blocks cell proliferation and growth - Famitinib: A multi-target tyrosine kinase inhibitor - Nab-paclitaxel: A taxane chemotherapy agent that disrupts microtubule function - Pyrotinib: An irreversible pan-HER inhibitor targeting EGFR/HER1, HER2, and HER4 This combination targets multiple cancer pathways simultaneously, including angiogenesis, immune checkpoints, cell growth signaling, and cell division.

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)Mechanistic target of rapamycin complex 1ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on bevacizumab + camrelizumab + everolimus + famitinib + nab-paclitaxel + pyrotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + camrelizumab + everolimus + famitinib + nab-paclitaxel + pyrotinib.

Explore the full profile